We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915‐918.
- Authors
Gando, Alejandro; Alexay, Sofia; Galán Núñez, Juan P.; Cano, Lucía N.; Diez, Roberto A.; Costa, Luis A.
- Abstract
In comparison with the case reported by Hadadi et al., we consider that the main differences are that our patients were not so critically ill as their patients and the presence of a simultaneous group of patients who only received standard care. REFERENCES 1 Hadadi A, Mortezazadeh M, Kolahdouzan K, Alavian G. Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects?.
- Subjects
RECOMBINANT erythropoietin; COVID-19; CRITICALLY ill; TREATMENT effectiveness; DRUG registration; CRITICALLY ill patient care
- Publication
Journal of Medical Virology, 2021, Vol 93, Issue 5, p2626
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.26879